Filing Flows › China Pharma Holdings (CPHI) › Q1 2026 › vs Q4 2025
China Pharma Holdings (CPHI) Q1 2026 vs Q4 2025 (quarter over quarter)
China Pharma Holdings's revenue fell $242K (-20%) from $1.2M in Q4 2025 to $984K in Q1 2026.
China Pharma Holdings, Q1 2026: revenue $984K (-13% year over year), operating margin -113.6%, net loss $1.1M, operating cash flow −$55K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $984K | $1.2M | −$242K | -20% |
| Net loss | $1.1M | $1.2M | −$79K | -6% |
| Costs & expenses | $2.1M | $2.4M | −$321K | -13% |
| Operating costs | $2.1M | $2.4M | −$325K | -13% |
| Interest & other, net | $26K | $22K | $4K | +18% |
| Cost of revenue | $698K | $1.1M | −$377K | -35% |
| Operating cash sources | $1.1M | $1.2M | −$79K | -6% |
| Depreciation & amortization | $981K | $497K | $483K | +97% |
| Working capital & other | $107K | $877K | −$769K | -88% |
| Cash used in operations | $55K | −$152K | $207K | — |
| Net loss absorbed | $1.1M | $1.2M | −$79K | -6% |
Questions
How much did China Pharma Holdings's revenue grow quarter over quarter in Q1 2026?
China Pharma Holdings's revenue fell $242K (-20%) from $1.2M in Q4 2025 to $984K in Q1 2026.